🌍 Keytruda, Merck’s $29.5B oncology juggernaut, faces a patent cliff by 2028. Who’s poised to disrupt its next chapter with a biosimilar?

Alvotech and Dr. Reddy’s Laboratories are making a bold play, partnering to co-develop and commercialize a pembrolizumab biosimilar. Leveraging Alvotech’s R&D prowess and Dr. Reddy’s global manufacturing and market reach, this alliance aims to capture share in the post-patent immuno-oncology market while driving down costs.

Dive into the full article to unpack how this strategic move could reshape access and competition in oncology.

#SyenzaNews #oncology #biosimilars #pharma #innovation

🔍 Are we overlooking the importance of transparency in peer review?

In a recent article from the BMJ, the debate surrounding the necessity of transparency in scientific research heats up. While some argue it adds unnecessary burdens, this perspective misses the critical role transparency plays in building trust and ensuring reproducibility in our findings.

Dive into how embracing openness not only enhances scientific integrity but also shapes effective health policies. Don’t miss the chance to elevate your understanding of transparency in research!

#SyenzaNews #HealthEconomics #HealthcarePolicy #Innovation

🔍 Are we creating a healthcare system that truly works for everyone?

Recent findings from EFPIA shed light on alarming inequities in access to medicines across Europe, showing that only 46% of approved drugs are available to patients this year. With significant delays affecting smaller markets and critical cancer treatments, this article explores the systemic barriers at play and innovative solutions proposed to ensure fair access.

Dive into the full article to uncover how we can collectively shape a more equitable healthcare landscape.

#SyenzaNews #healthcare #MarketAccess